|Facial Effects of the Warner Protocol for Children with Down Syndrome||Author article list|
Robert J. Thiel, Ph.D., N.M.D.
Journal of Orthomolecular Medicine, 2002, 17(2):111-116
Reprinted with the permission of the Journal of Orthomolecular Medicine|
Background: Children with Down syndrome tend to have unique facial characteristics which make them identifiable on the basis of appearance only. Since 1986, Dr. F. Jack Warner has specialized in seeing people with Down syndrome. Warner uses an unconventional protocol which includes interventions such as nutrition (HAP Caps, flaxseed oil, N, N-dimethylglycine), physical therapy, ophthalmology, and conventional medicine. Warner claims his interventions can help make children with Down syndrome more like non-Down's children. The purpose of this investigation was to determine if the Warner protocol can improve facial features for children with Down syndrome.Introduction
Method: This investigation used a pretest-posttest, natural control group design. An independent investigation of a random sample of Warner's records was performed. Height and weight data, based on age, were compared against growth grids for Down's children for two visits to the Warner House: the initial measurement and the final measurement.
Results: An analysis of the sample suggests that the combined interventions appear to significantly improve facial features for children with Down syndrome.
Conclusion: Nutrition may be the most likely intervention to be credited for improving facial features. A prospective study to test this position should be performed.
The nutritional interventions used by Warner House are a combination of a multiple vitamin/mineral formula called "HAP Caps" (HAP stands for Health and Progress), plus flaxseed oil (1-3 teaspoons normally recommended), N,N-dimethylglycine (an amino acid derivative, with 30-500 mg normally recommended), and sometimes other nutritional substances. Each HAP Caps capsule contains beta carotene 2000 I.U., vitamin B-1 6.25 mg, vitamin B-2 6.25 mg, vitamin B-3 6.25 mg, calcium pantothenate 25 mg, vitamin B-6 6.25 mg, vitamin B-12 1.25 mcg, vitamin C 100 mg, vitamin D-3 33 I.U., biotin 25 mcg, vitamin E 33 I.U., choline 50 mg, folic acid 50 mcg, inositol 5 mg, PABA 75 mcg, cobalt 5 mcg, iron 5 mg, manganese 125 mcg, copper 40 mcg, molybdenum 75 mcg, selenium 7.5 mcg, zinc 2.5 mg, organic iodine (from kelp) 18.75 mcg, rutin (a bioflavonoid) 25 mcg, quercitin (a bioflavonoid) 6 mg, liver extract (bovine) 6.25 mg, betaine hydrochloride 1.8 mg, ox bile 3.6 mg, pancreatin (supplies enzymes) 2.8 mg, co-enzyme Q10 8 mg, and the amino acids glutamine 75 mg, taurine 4 mg, and tyrosine 55 mgthe number of capsules recommended varies by patient weight  and normally ranges from 2-12 per day (approximately 1 HAP Cap per 10 lbs.). HAP Caps have a similar composition to the 'U' series nutrients that Dr. Turkel pioneered decades previously (which Turkel safely used for thousands with Down syndrome ). The Warner House recommends physical therapy for all trisomy patients. It also advises that all with trisomy 21 disorders avoid cow's milk products. Ophthamological interventions, interventions for infections, thyroid medications, and other conventional medical interventions are recommended when indicated.
At Warner House, two photographs are taken at the initial appointment, a front photograph and a side (profile) photograph by a staff member; follow-up photographs are normally taken by the same staff member or sometimes is sent in by the parents. This specific investigation used a pretest-posttest, natural control group design.
Facial features were analyzed by reviewing photographs under lighted magnification. The three features assessed were degree of facial swelling, development of a nose bridge, and epicanthal folds of the eye. "The face of a person with Down syndrome is characterized by flatness and small centrally placed features. The flatness is accentuated by the broad, flat nose...flat-bridged nose" . Down's patients have been described as an having an "underdeveloped midface" while Down's infants have been described to have 'chubby cheeks"  and "facial edema" has also been noted . "Epicanthal folds are defined as a fold of skin covering all or part of the medial canthal region and conjunctival caruncle, the medial transitional zone between skin, and medial bulbar conjunctiva" . A ten point scale was developed with zero signifying normal for children without Down syndrome and to a maximum of ten signifying an appearance consistent with the more pronounced presentation of this feature. For example, a lack of any noticeable (or completely flat) nose bridge would receive a score of 10, whereas a completely normal appearing nose bridge would receive a score of zero.
Some data was excluded if it was unclear from the photographs. Regarding the nose bridge, those photographs of patients wearing glasses were normally excluded; for epicanthal fold those photographs (mainly of infants) whose eyes were closed or those whose ancestry pre-disposed them for an epicanthal fold were normally excluded.
Warner made all of his non-archived files available. Files were randomly selected using a random number table. Files were accepted if they had initial and final age, combined with initial and final photographs with adequately discernible features. As this investigation was limited to children, files for patients with ages above 16.0 were excluded. Of the selected files, 85 met the criteria for reviewing facial swelling, 82 for nose bridge, and 81 for epicanthal fold. Approximately 1,500 non-archived records were estimated to be available which met these criteria.
This investigation was pre-approved by an independent review board.
85 of the records selected were analyzed to discern facial swelling/edema as shown in Table 1.
|Gender||N||Attibute||Initial Mean||Final Mean||Percent
|on 10 Point Scale|
65 of the 85 had improved facial swelling improvement. The data was analyzed utilizing regression analysis. Gender differences were statistically significant as males improved much more than females (57.6% improvement vs. 28.8% improvement). The average (mean) age at the initial appointment was 2.2 years whereas the average age at the final appointment was 5.2 years.
82 of the records selected were analyzed to discern the formation of a normal nose bridge as shown in Table 2.
|Gender||N||Attibute||Initial Mean||Final Mean||Percent
|on 10 Point Scale|
62 of the 82 had improved nose bridge appearance. The data was analyzed utilizing regression analysis. Unlike facial swelling, the gender differences were not statistically significant. The average (mean) age at the initial appointment was 2.2 years whereas the average age at the final appointment was 5.1 years.
81 of the records selected were analyzed to discern the amount of epicanthal eye fold as shown in Table 3.
|Gender||N||Attibute||Initial Mean||Final Mean||Percent
|on 10 Point Scale|
56 of 81 had improvement in the epicanthal fold appearance. The total data was analyzed utilizing regression analysis. Gender differences were not statistically significant. The average (mean) age at the initial appointment was 2.3 years whereas the average age at the final appointment was 5.2 years.
The advocacy of an interdisciplinary approach for Down syndrome patients predates Dr. Warner's involvement . The fact that children undergoing the Warner protocol showed significant improvement in appearance seems to suggest that interventions such as those used by Warner are helpful when begun at an early age. Others using similar formulas have also claimed that nutrition can improve facial features. Turkel, probably the best known pioneer of using nutrition for those with Down syndrome, includes many before and after photographs in his book, Medical Treatment of Down Syndrome and Genetic Disorder, to demonstrate the improvement . Turkel's work, as well as this investigation of Warner House, suggest that appearance can be improved. This is not to say that children with Down syndrome who follow the Warner protocol will no longer be identifiable as having Down syndrome on the basis of appearance only, but that they will tend to develop a more normal appearance.
There have been case reports that other nutrients can also affect appearance. Two years after taking a supplement containing essential monosaccharides, Michelle Desrochers showed facial improvement in all the areas that this study covered . There is also a case report that indicated that injections of dimethyl sulfoxide (DMSO), gamma amino butyric acid (GABA), gamma-aminobeta-hydroxybutric acid (GABOB), and acetylcholine helped improve appearance for another child with Down syndrome .
Triplication of the 21st chromosome causes metabolic disturbances which lead to an accumulation of various metabolic precursors and a deficiency of certain end productsthis is one of the basic reasons why nutritional interventions make scientific sense for persons with Down syndrome [8,14,15]. It has been claimed that it may only be a particular region of the 21st chromosome (band 21q22) that causes the features which are associated with Down syndrome . Beyond that, some believe that it is the high level of free radicals and imbalance of antioxidants that lead to the distinctive changes in appearance associated with Down syndrome . Superoxide dismutase and alpha and beta-interferon levels are elevated for those with Down syndrome [2,17]. It has been hypothesized that supplemental vitamin E may reduce superoxide dismutase-generated oxidative damage in Down syndrome patients ; it has also been speculated that supplementation with other antioxidant nutrients can do the same thing [15,19]. Levels of alanine, cysteine, isoleucine, lysine, phenylalanine, and threonine seem to be elevated, yet tyrosine, folate, manganese, iron, thiamin, vitamin B12, vitamin C, vitamin E, and selenium levels appear to be depressed (additional nutrients have also been implicated) [8,20-23]. Some minerals, such as calcium and magnesium, seem to be higher than non-Down's patients in some areas of the body, yet lower in others areas [8,20]. It has been speculated that the alteration of the conjunctival epithelium in patients with Down syndrome may be due to altered metabolism of vitamin A . Disorders of vitamin D metabolism have also been speculated for Down's patients [8,25], and since vitamin D does affect bone development, it probably plays a role in appearance. It simply makes sense to this researcher that if nutrition is abnormal, that appearance can be affected, and that appropriate supplementation can help and should be considered. Furthermore, it has been shown that people with Down syndrome who display the more pronounced facial features are simply not viewed as well by society .
Down's patients are more susceptible to certain ophthalmological problems than the general public (most notably strabismus) which leads to distortion of vision . Early ophthamological interventions, such as provided by Warner House, could be expected to lead to improved vision. It does not seem likely, though, that this would affect nose bridge or epicanthal folds. It is of further interest to note that a study of an ophthalmological nature concluded "that between the ages of 7 and 14 years, facial characteristics of children with Down syndrome do not change with age" . For children whose first and last photograph were between 7 and 14 years of age, a subset of Warner's records suggest that facial features did change for the positive with 84.4%, 6.3%, and 63.5% improvement for facial swelling, nose bridge, and epicanthal fold respectivelythe low improvement for nose bridge (6.3%) suggests this area improves little during this stage of development.
Physical therapy, such as recommended by Warner House, could be expected to improve muscle tone. Some reports suggest that physical therapy could have some effects on appearance and intelligence of those with Down syndrome, especially when used as part of a multidisciplinary approach [28-29]. One study involving the Castillo Morales method concluded that the symptoms "tongue mostly protruding over the lips" and "mouth wide open" were reduced , which are not determinable features from examining photographs at Warner's clinic. Some of the osteopathic literature suggests that osteopathic manipulation can be helpful to normalize facial features for children with Down syndrome .
Although this investigation was preliminary, it appears that there is some efficacy in the Warner protocol regarding facial features. As the Warner protocol combines nutrition with physical therapy, medicine, and ophthalmology, it is not possible to statistically segregate the impact of any one of those interventions. It is possible that all of the interventions may work synergistically to improve facial appearance or that one or more interventions on its own has the most (or the entire) effect. Nutrition probably has the greatest effect on appearance, with physical therapy probably having the next largest impact. A prospective study would be needed in order to assess the possible impact of any single intervention. This investigator believes that the data in this paper favorably support the need for such a study.
 Cotran RS, Kumar V, Collins T. Pathologic Basis of Disease, 6th ed. WB Saunders, Phil., 1999
 Kissane JM. Anderson's Pathology, 9th ed. CV Mosby Co., St. Louis, 1990
 Fink GB, Madaus WK, Walker GF. A quantitative study of the face in Down's syndrome. Am J Orthod, 1975;67(5):540-553
 Jones RB. Parental consent to cosmetic facial surgery in Down's syndrome. J Med Ethics, 2000:26(2):101-102
 Van Dyke DC, Van Dyke S, Lowe O, Heide F. Alternative and controversial therapies. In Clinical Perspectives in the Management of Down Syndrome. Springer-Verlag, NY, 1990:208-216
 Klaiman P, Arndt E. Facial reconstruction in Down syndrome: perceptions of the results by parents and normal adolescents. Cleft Palate J, 1989;26(3):186-192
 Warner FJ. A Quiet Population Demands Good Health. Warner House, Fullerton (CA), 1993
 Turkel H, Nusbaum I. Medical Treatment of Down Syndrome and Genetic Diseases, 4th ed. Ubiotica, Southfield (MI), 1985
 Arino P, Aguado L, Cortada V, Baltasar M, Puig MM. Cold uticaria associated with intraoperative hypotension and facial edema. Anesthesiology 1999;90(3):907-909
 Fierson WM. Opthalmological aspects. In Clinical Perspectives in the Management of Down Syndrome. Springer-Verlag, NY, 1990:27-54
 Connolly B, Russell F. Interdisciplinary early intervention program. Phys Ther,1976;56(2):155-158
 Sant, K. Necessity the mother of inventions. Las Vegas Magazine 2001; July/August:51
 Walker M. DMSO & Downs: using amino acid therapy for Down's syndrome. Healthy & Natural J, circa 1997:54-56
 Arbuzova SB. Free radicals in the origin and clinical manifestation of Down's syndrome. Tsitol Genet, 1996;30(2):25-34
 Elliot P. Proposed randomized, controlled trial of the effects of antioxidants and folinic acid supplementation on the mental development, growth, and health of children with Down syndrome. Down Syndrome Medical Interest Group Meeting, San Diego, July 8, 2001
 Korenberg JR, Kawashima H, Pulst SM, Ikeuchi T, Ogasawara N, Yamamoto K, Schonberg SA, West R, Allen L, Magenis E, et al. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet, 1990;47(2):236-246
 Teksen F, Sayli BS, Aydin A, Sayal A, Isimir A. Antioxidant metabolism in Down syndrome. Biol Trace Elem Res, 1998;63(2):123-127
 Sylvester PE. Ageing in the mentally retarded. In Scientific Studies in Mental Retardation. MacMillian, London, 1984:259-277
 Warner FJ, Stephens C. Metabolic supplementation for correction of raging free radicals in trisomy 21. Presentation at the International Down's Conference. Madrid, Spain, 1997
 Werbach MR. Textbook of Nutritional Medicine. Third Line Press, Tarzana (CA), 1999
 Hamilton K. Down syndrome: selenium supplementation and trace elements. Clinical Pearls Currents, 1994; 4(3):46
 Anneren G, Magnusson CG, Nordvall SL. Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down's syndrome. Arch Dis Children, 1990;65:1353-1355
 Heggarty HJ, Ball R, Smith M, Henderson MJ. Amino acid profile in Down's syndrome. Arch Dis Childhood, 1996;74:377-349
 Filippello M, Cascone G, Zagami A, Scimone G. Impression cytology in Down's syndrome. Br J Opthalmol,1997;81(8):683-685
 Center J, Beange H, McElduff A. People with mental retardation have an increased prevalence of osteoporosis. Am J Ment Retard,1998;103(1):19-28
 Fidler DJ, Hodapp RM. Cranialfacial maturity and perceived personality in children with Down syndrome. Am J Ment Retard, 1999;104(5):410-421
 Woodhouse JM, Hodge SJ, Earlam RA. Facial characteristics in children with Down's syndrome and spectacle fitting. Ophthalmic Physiol Opt, 1994;14(1):25-31
 Gibson D, Harris A. Aggregated early intervention effects for Down's syndrome persons: patterning and longevity of benefits. J Ment Defic Res,1988;32(Pt 1):1-17
 Limborck GJ, Fisher-Brandies H, Avalle C. Castillo-Morales' orofacial therapy: treatment of 67 children with Down's syndrome. Dev Med Child Neurol,1991;33(4):296-303
 Hohoff A, Ehmer U. Short-term and long-term results after early treatment with the Castillo Morales stimulating plate: a longitudinal study. J Orofac Orthop, 1999;60(1):2-12
 Sorrell, MA. Osteopathic treatment of Down syndrome children. The Cranial Letter, 1995:48(2): 4-7